Insight Molecular Diagnostics Inc(IMDX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 27 at 4:00 PM ET (Korea 10/28 05:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.49 | Insider Own | 68.77% | Shs Outstand | 32.6M | Perf Week | 4.29% |
| Market Cap | 0.10B | Forward P/E | - | EPS next Y | 4.82% | Insider Trans | 2.6% | Shs Float | 10.2M | Perf Month | -0.63% |
| Enterprise Value | 0.09B | PEG | - | EPS next Q | -0.24 | Inst Own | 18.8% | Short Float | 9.29% | Perf Quarter | -27.69% |
| Income | -0.05B | P/S | 61.92 | EPS this Y | 45.18% | Inst Trans | -6.75% | Short Ratio | 3.91 | Perf Half Y | -24.76% |
| Sales | 0.00B | P/B | - | EPS next 5Y | 27.84% | ROA | -123.46% | Short Interest | 0.95M | Perf YTD | -57.87% |
| Book/sh | -0.65 | P/C | 5.6 | EPS past 3/5Y | 50.09% 29.01% | ROE | -23603.11% | 52W High | -62.87% ($8.51) | Perf Year | -51.38% |
| Cash/sh | 0.56 | P/FCF | - | Sales past 3/5Y | 61.76% 27.24% | ROIC | - | 52W Low | 30.58% ($2.42) | Perf 3Y | 38.6% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 57.26% | Gross Margin | -93.38% | Volatility(W/M) | 8.42% 10.86% | Perf 5Y | -95.11% |
| Dividend TTM | - | EV/Sales | 52.42 | Sales Y/Y TTM | -60.77% | Oper. Margin | -2217.9% | ATR (14) | 0.32 | Perf 10Y | -96.15% |
| Dividend Ex-Date | - | Quick Ratio | 1.98 | EPS Q/Q | -0.72% | Profit Margin | -2955.63% | RSI (14) | 46.41 | Recom | 1.8 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2 | Sales Q/Q | -53.86% | SMA20 | -0.39% ($3.17) | Beta | 1.89 | Target Price | $8.25 |
| Payout | - | Debt/Eq | - | Earnings | 2026/8/10 | SMA50 | -14.53% ($3.7) | Rel Volume | 1.26 | Prev Close | $3 |
| Employees | 58 | LT Debt/Eq | - | EPS/Sales Surpr. | -22.05% -32.2% | SMA200 | -34.09% ($4.79) | Avg Volume(3M) | 0.24M | Price | $3.16 |
| IPO | 2015/12/30 | Option/Short | Yes/Yes | Trades | 1626 | Volume | 306,880 | Change | 5.33% |
🧬 Insight Molecular Diagnostics (IMDX) is a healthcare company developing molecular diagnostic technologies for organ transplant patients. Its core focus is a technology that quantifies donor-derived cell-free DNA (dd-cfDNA), and it is also expanding commercialization through diagnostic partnerships. The company is establishing itself as a molecular diagnostics platform that addresses the clinical need for early detection of transplant rejection.
Over the past 1 year, on the lower side
63% below its 1-year high.
Traded more than usual. That is 126% of its average volume.
IMDX has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +45.2% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $6,192. Peers typically go for $451.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -95.1%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 18.8%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #36 of 44 in the industry
Based on market cap of $103M.
BDSX#33 Biodesix Inc $232M PER - 
XGN#34 Exagen Inc $188M PER - 
BNR#35 Burning Rock Biotech Ltd ADR $104M PER - IMDX#36 Insight Molecular Diagnostics Inc $103M PER - 
QUCY#37 Quantum Cyber NV $79M PER - 
FAQ
What kind of company is IMDX?
IMDX belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is the market cap of IMDX?
The market cap of IMDX is approximately $103M, ranking 4,449 within its sector.
What is the 52-week high and low for IMDX?
IMDX has recorded a 52-week high of $8.51 and a low of $2.42.
